Cerevel Therapeutics Holdings, Inc.

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
40.31 ^USD	-1.80%		-1.59%	-4.93%

Jul. 01	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	CI
Jul. 01	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	CI

Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index

July 30, 2024

Latest news about Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Growth Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Growth Index	Jun. 30	CI
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	May. 14	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	Apr. 18	MT
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	Apr. 18	RE
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	Apr. 18	CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	Mar. 04	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22	MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	Feb. 22	MT
Phew! The party continues!	Feb. 22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	Feb. 21	RE
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN

Chart Cerevel Therapeutics Holdings, Inc.

Duration

Period

Chart Cerevel Therapeutics Holdings, Inc.

More charts

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.31 USD

Average target price

44.71 USD

Spread / Average Target

+10.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CEREVEL THERAPEUTICS HOLDINGS, INC.	-4.93%	7.48B
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	127B
REGENERON PHARMACEUTICALS, INC.	+25.25%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.51%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-15.63%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs